Development of an icIEF assay for monitoring AAV capsid proteins and application to gene therapy products

被引:10
|
作者
He, Xiaoping Z. [1 ,2 ]
Powers, Thomas W. [1 ]
Huang, Sisi [1 ]
Liu, Zhenjiu [1 ]
Shi, Heliang [1 ]
Orlet, John D. [1 ]
Mo, Jim J. [1 ]
Srinivasan, Saipraveen [1 ]
Jacobs, Steven [1 ]
Zhang, Kun [1 ]
Runnels, Herbert A. [1 ]
Anderson, Melissa M. [1 ]
Lerch, Thomas F. [1 ]
机构
[1] Pfizer Inc, Analyt Res & Dev, Chesterfield, MO USA
[2] Pfizer Inc, Analyt Res & Dev, 875 Chesterfield Pkwy West, Chesterfield, MO 63017 USA
关键词
MONOCLONAL-ANTIBODIES; EXPRESSION; VECTORS; TROPISM;
D O I
10.1016/j.omtm.2023.03.002
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Adeno-associated virus (AAV) gene therapy vectors, which contain a DNA transgene packaged into a protein capsid, have shown tremendous therapeutic potential in recent years. Methods traditionally used in quality control labs, such as high-performance liquid chromatography (HPLC) and capil-lary electrophoresis (CE), do not provide a complete under-standing of capsid viral protein (VP) charge heterogeneity. In the present study, we developed simple, one-step sample prep-aration and charge-based VP separation using imaged capillary isoelectric focusing (icIEF) for monitoring AAV products. The robustness of the method was confirmed through a design of experiments (DoE) exercise. An orthogonal reverse-phase (RP) HPLC method coupled with mass spectrometry was devel-oped to separate and identify charge species. Additionally, capsid point mutants demonstrate the capability of the method to resolve deamidation at a single site on the viral proteins. Finally, case studies using two different AAV serotype vectors establish the icIEF method as stability indicating and demon-strate that increases in acidic species measured by icIEF corre-late with increased deamidation, which, we show, results in decreased transduction efficiency. The addition of a rapid and robust icIEF method to the AAV capsid analytical toolkit enables development and consistent manufacturing of well -characterized gene therapy products.
引用
收藏
页码:133 / 144
页数:12
相关论文
共 50 条
  • [21] Gene Therapy for Mucolipidosis IV Using Novel CNS-Targeted AAV Capsid
    Grishchuk, Yulia
    Sangster, Madison
    Bishop, Martha
    Miller, Maxwell
    Chekuri, Anil K.
    Yao, Yizheng
    Bei, Fengfeng
    MOLECULAR THERAPY, 2023, 31 (04) : 134 - 134
  • [22] A Novel Rationally Designed AAV Capsid Yields a Potent Neurotropic Gene Therapy Vector
    Henckaerts, Els
    Tordo, Julie
    Palomar, Nuria
    Rahman, Jahedur
    Aldrin-Kirk, Patrick
    Basche, Mark
    Bennett, Antonette
    O'Leary, Claire
    Ali, Robin
    Agbandje-McKenna, Mavis
    Bigger, Brian
    Rahim, Ahad A.
    Bjorklund, Tomas
    Waddington, Simon
    Linden, R. Michael
    MOLECULAR THERAPY, 2016, 24 : S101 - S101
  • [23] Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors
    Pekrun, Katja
    De Alencastro, Gustavo
    Luo, Qing-Jun
    Liu, Jun
    Kim, Youngjin
    Nygaard, Sean
    Galivo, Feorillo
    Zhang, Feijie
    Song, Ren
    Tiffany, Matthew R.
    Xu, Jianpeng
    Hebrok, Matthias
    Grompe, Markus
    Kay, Mark A.
    JCI INSIGHT, 2019, 4 (22)
  • [24] Immune Response to AAV Vector Capsid and Assessment of Eligibility for AAV-Mediated Gene Therapy for Duchenne Muscular Dystrophy
    Saha, Rima
    Meyers, Craig
    Coleman, Kirsten
    Trivedi, Prasad
    Bhake, Radhika
    Byrne, Barry J.
    Corti, Manuela
    MOLECULAR THERAPY, 2023, 31 (04) : 546 - 547
  • [25] Development of an In Vitro Potency Assay for an AAV Gene Therapy Delivering a Functional Version of SHANK3
    Murphy, Michael A.
    De Petrillo, Michael
    Bauldwin, Kalyn
    MOLECULAR THERAPY, 2024, 32 (04) : 877 - 877
  • [26] Development of a robust potency assay: the gateway to understanding the structure-function relationship in AAV gene therapy
    Natu, K.
    Fandunyan, E.
    Horton, R.
    Brazell, B.
    Smith, C.
    Burnham, B.
    Lushi, R.
    Michel, E.
    Slater, C.
    McColl-Carboni, A.
    McGivney, J.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A98 - A98
  • [27] In Vivo Potency Assay for AAV-Based Gene Therapy Vectors
    De, Bishnu P.
    Chen, Alvin
    Rosenberg, Jonathan B.
    Chiuchiolo, Maria
    Van de Graaf, Benjamin
    Pagovich, Odelya E.
    Sondhi, Dolan
    Russo, Carlo
    Kaminsky, Stephen M.
    Crystal, Ronald G.
    MOLECULAR THERAPY, 2016, 24 : S186 - S186
  • [28] Choroideremia: molecular mechanisms and development of AAV gene therapy
    Patricio, Maria I.
    Barnard, Alun R.
    Xue, Kanmin
    MacLaren, Robert E.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (07) : 807 - 820
  • [29] Potency Method Development Roadmap for AAV Gene Therapy
    Beattie, Kimberley
    MacArthur, Michael
    Nattyaba, Martha
    Fandunyan, Eugenia
    Natu, Kalyani
    MOLECULAR THERAPY, 2024, 32 (04) : 287 - 287
  • [30] Development of AAV gene therapy for Morquio syndrome type A
    Tomatsu, Shunji
    Sawamoto, Kazuki
    Kahn, Shaukat
    Stapleton, Molly
    Melethil, Subha
    Danos, Olivier
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S144 - S145